TECHNICAL PROGRAM - American Chemical Society Publications

232. Bisphosphonate analogs of geranyl and
farnesyl pyrophosphate as potential inhibitors
of prenyl synthases.
M. A. Maalouf, B. M. Wasko, R. J. Hohl,
D. F. Wiemer
233. Design and synthesis of folate conjugates
of Rapamycin and Everolimus.
I. R. Vlahov, P. J. Kleindl,
H. R. Santhapuram, J. F. Vaughn,
S. J. Han, F. You, Y. Wang, C. P. Leamon
234. Discovery of TAK-438: Synthesis and
biological evaluation of novel pyrrole derivatives
as potassium-competitive acid
blockers (P-CABs). Y. Arikawa,
H. Nishida, A. Hasuoka, O. Kurasawa,
K. Hirase, N. Inatomi, Y. Hori,
J. Matsukawa, N. Tarui, A. Imanishi,
M. Kondo, Y. N. Imai, M. Kajino
235. Series of non-covalent inhibitors of the
human 20S Proteasome derived from
N-�-neopentyl asparagine with unprecedented
potency and selectivity.
C. Blackburn, C. Barrett, N. Bump,
F. Bruzzese, L. Dick, P. Fleming,
K. Garcia, K. Gigstad, P. Hales,
L. Herman, M. Jones, J. Liu, D. Sappal,
M. Sintchak, C. Tsu, J. Blank
236. Total synthesis of racemic and natural
glyceollin II. A. Luniwal, P. W. Erhardt
237. Genomics guided medicinal chemistry.
E. Beausoleil, T. Taverne,
C. Chauvignac, B. Leblond, D. Pallares,
M. Brenner, M. Pando
238. De-convolution of medicinal citrus
products. S. Li,N.E.Rawson,C.Ho
239. Utilization of DNA-encoded libraries for
the identification of novel inhibitors of
prolyl hydroxylases. D. T. Fosbenner,
B. W. King, K. K. Brown, P. Keller,
K. McKenzie, B. Siegfried, L. Mitchell,
A. Smallwood, N. Concha, L. Miller,
Y. Xue, G. J. Franklin, P. A. Centrella,
J. Svendsen, S. Mataruse, M. A. Clark
240. Oxyphors R3 and G3 — new phosphorescent
probes for tissue oxygen measurements:
Synthesis and characterization.
T. V. Esipova, S. A. Vinogradov
241. Synthesis of rosmarinic acid analogs.
G. A. Kraus, G. R. Pollock III
242. Overexpression, isolation, and oral delivery
of the appetite suppressant peptide
PYY. C. H. Fazen,R.P.Doyle
243. Using haptocorrin and intrinsic factor as
oral delivery agents. D. Valentin,
R. P. Doyle
244. Benzo[d]imidazole/indole inhibitors of
coactivator associated arginine methyltransferase
1 (CARM1). H. Wan,
T. Huynh, S. Pang, J. Geng, T. Bandiera,
S. Bindi, P. Vianello, F. Roletto,
S. Thieffine, A. Galvani, W. Vaccaro,
M. A. Poss, G. L. Trainor, M. V. Lorenzi,
M. Gottardis, L. Jayaraman,
A. V. Purandare
MONDAY MORNING
Section A
Boston Convention & Exhibition Center
Ballroom West
G-Quadruplexes as Targets for Drug
Discovery and Development
L. Hurley, D. Yang, Organizers, Presiding
8:30 245. Quadruplex nucleic acids as functional
elements and therapeutic targets.
S. Balasubramanian
9:10 246. Overview of G-quadruplexes, their
biological role, and G-quadruplex structures.
D. Yang
9:50 247. Structure-based design and evaluation
of small molecules with selectivity
for telomeric quadruplex nucleic acids.
M. Gunaratnam, S. Hempel, G. Collie,
S. Sparapani, N. Campbell, G. Parkinson,
M. de la Fuente, A. Schatzlein, S. Neidle
10:30 248. Drug targeting of the c-Myc
G-quadruplex and associated proteins to
inhibit gene transcription. L. H. Hurley
Section B
Boston Convention & Exhibition Center
Room 253A/B
Effects of Free Drug on In Vivo Efficacy
J. Butera, Organizer
L. Di, E. Kerns, Organizers, Presiding
8:30 249. Free fraction, free drug concentration
and in vitro to in vivo extrapolation-no
common consensus on a common
problem. D. A. Smith
9:05 250. Considerations of protein binding
in CNS drug design. X. Liu,C.E.Hop
9:40 251. Determinants of drug disposition
in tumors. J. M. Gallo
10:15 252. Managing plasma protein binding.
G. L. Trainor
10:50 253. Changes in protein binding:
When can they be clinically relevant?
L. Z. Benet
11:25 Panel Discussion
Open-source Drug Discovery Sponsored by
BMGT, Cosponsored by CPCD, MEDI, and
NESACS
Tautomers and Biology
Predictions of Tautomer Ratios Sponsored
by COMP, Cosponsored by CINF, MEDI, and
PHYS
The Community Structure-Activity
Resource (CSAR) Scoring Challenge
Sponsored by COMP, Cosponsored by BIOL,
CINF, and MEDI
MONDAY AFTERNOON
Section A
Boston Convention & Exhibition Center
Ballroom West
Recent Developments in Investigational
Therapies for HCV
A. Palani, A. Arasappan, A. Stamford,
W. Kazmierski, Organizers, Presiding
2:00 254. Discovery of telaprevir. A. Grillot
2:30 255. Novel noncovalent inhibitors of
the HCV serine protease. P. J. Edwards,
M. D. Bailey, P. K. Bhardwaj, M. Bös,
M. G. Cordingley, P. Forgione,
N. Goudreau, C. Lemke, P. W. White,
M. Llinàs-Brunet
3:00 256. Discovery of potent HCV inhibitors
targeting the NS5A protein. M. Belema,
V. N. Nguyen, J. L. Romine,
D. R. St. Laurent, M. H. Serrano-Wu,
L. B. Snyder, M. S. Deshpande,
R. A. Fridell, D. R. O’Boyle II, J. A. Lemm,
J. E. Leet, J. O. Knipe, D. R. Langley,
R. E. Nettles, C. Chien, R. J. Colonno,
D. M. Grasela, N. A. Meanwell,
L. G. Hamann, M. Gao
3:30 257. HCV NS4A antagonists.
A. Phadke, X. Wang, D. Chen,
V. Gadhachanda, A. Hashimoto,
M. Deshpande, M. Huang
4:00 258. Benzofuran inhibitors of HCV
NS5b polymerase: An in-depth look at
SAR and pre-clinical characteristics that
let to the advancement of HCV-796 into
human clinical studies. A. K. Saha
4:30 259. Discovery and development of 2�-
F-2�-C-methyl nucleosides and nucleotides
for the treatment of HCV.
M. J. Sofia
Section B
Boston Convention & Exhibition Center
Room 253A/B
Drugging the Undruggable: Small Molecule
Modulators of Protein-Protein Interactions
D. Hertzog, E. Velthuisen, Organizers,
Presiding
2:00 260. Principles of protein-protein interactions:
What is the preferred way for
proteins to interact? R. Nussinov
2:30 261. Synthesis and evaluation of libraries
designed to modulate protein-protein
and protein-DNA interactions.
D. L. Boger
3:00 262. Protein-protein interaction inhibitors
of transcription factors and kinases.
T. Berg
3:30 263. Drugging the undruggable using
stapled peptides. G. L. Verdine
4:00 264. Small molecule inhibitors of protein-protein
interactions: Targeting Bcl-2
family proteins to treat cancer.
S. W. Elmore
Open-source Drug Discovery Sponsored by
BMGT, Cosponsored by CPCD, MEDI, and
NESACS
The Chemistry of Epigenetic Regulation
Sponsored by BIOL, Cosponsored by MEDI
The Community Structure-Activity
Resource (CSAR) Scoring Challenge
Sponsored by COMP, Cosponsored by BIOL,
CINF, and MEDI
Undergraduate Research Posters
Medicinal Chemistry Sponsored by CHED,
Cosponsored by MEDI and SOCED
Using Waters Explicitly in Drug Discovery
Characterization and Applications
Sponsored by COMP, Cosponsored by CINF
and MEDI
Women at the Forefront of Preventing and
Combating Disease Sponsored by WCC,
Cosponsored by BIOL,MEDI, and PROF
MONDAY EVENING
Section A
Boston Convention & Exhibition Center
Hall C
Sci-Mix
J. Zablocki, Organizer
8:00–10:00
37, 39, 41, 42, 48, 60, 64, 65, 67, 68, 72, 75,
76, 77, 78, 91, 93, 96, 98, 116, 117, 118,
119, 120, 121, 122, 123, 124, 129, 130,
131, 135, 153, 195, 208, 209, 220, 221,
226. See previous listings.
484. See subsequent listings.
TUESDAY MORNING
Section B
Boston Convention & Exhibition Center
Room 253A/B
MEDI Awards Symposium
L. Hurley, J. Mc Carthy, Organizers
P. Woster, Presiding
8:00 265. JANUVIA® and beyond: Selective
dipeptidyl peptidase IV inhibitors for the
treatment of type 2 diabetes. A. E. Weber
8:40 266. Bioorganic studies on recognition
of soluble amyloid oligomers using small
molecules. N. W. Smith, S. V. Dzyuba
8:55 267. Application of aminoglycoside-Nacetyltransferases
in the development of
novel N-acylated aminoglycoside antibiotics.
J. L. Houghton,
S. Garneau-Tsodikova, M. Fridman,
K. Green, W. Chen
9:10 268. Designing attenuated Michael acceptors
as experimental redox chemotherapeutics
targeting skin cancer.
C. M. Cabello, G. T. Wondrak
9:25 269. Small molecule glycosaminoglycan
mimics. A. M. Fenner,R.J.Kerns
9:40 270. Discovery of a pharmacophore for
inhibition of poly(ADP-ribose) glycohydrolase.
J. D. Steffen, L. Steffen,
D. Coyle, M. K. Jacobson
9:55 271. Exploring Alphanapthoflavone
heterotropic allosteric regulation of Cytochrome
P450 3A4. C. M. Woods,
W. M. Atkins, C. Fernandez
10:10 272. Rational design of Tubastatin A:
An immunosuppressant HDAC6 inhibitor
with unprecedented selectivity. K. Butler,
J. Kalin, C. Brochier, B. Langley,
W. Hancock, G. Vistoli, A. Kozikowski
10:25 273. Evaluation of a direct procaspase
activating compound in pet
dogs with lymphoma. Q. P. Peterson,
D. C. West, D. C. Hsu, T. M. Fan,
P. J. Hergenrother
10:40 274. Heterocyclization in cyanobactin
biosynthesis. J. A. McIntosh
10:55 275. Discovery of novel BACE1 inhibitors
for the treatment of Alzheimer’s disease.
A. W. Stamford
Section A
Boston Convention & Exhibition Center
Ballroom West
Process Chemistry: The Role of Organic
Synthesis in Early Clinical Drug
Development Cosponsored by ORGN ‡
A. Abdel-Magid, Organizer
R. A. Singer, Organizer, Presiding
8:30 Introductory Remarks
8:35 276. Development of a scalable process
for p38 inhibitor VX-702. S. Roeper
9:15 277. Continuing process development
for existing HIV/AIDS drugs: Improving
access to medicines in the developing
world. D. S. Teager, D. H. Ripin,
R. Stringham, J. Fortunak
9:55 278. Discovery and development of
scalable routes to prepare AMG-221.
K. B. Hansen
10:35 279. Development of a scaleable process
for the production of a small molecule
clinical candidate. S. H. Wagaw
11:15 280. Catalytic asymmetric reactions in
the synthesis of complex drug targets.
A. Klapars,K.R.Campos,
J. H. Waldman, C. Chen
Oligonucleotide Therapeutics Sponsored by
CARB, Cosponsored by ANYL, BIOL, MEDI,
and ORGN
Tautomers and Biology
Tautomers and Macromolecule-ligand
Complexes Sponsored by COMP,
Cosponsored by CINF, MEDI, and PHYS
The Community Structure-Activity
Resource (CSAR) Scoring Challenge
Sponsored by COMP, Cosponsored by BIOL,
CINF, and MEDI
TUESDAY AFTERNOON
Section A
Boston Convention & Exhibition Center
Room 153A/B/C
Lunch and Learn Case Study: Chemistry
and Pharmaceutical Blogging
An Important Means of Non-Traditional
Scientific Communication
T. Bannister, C. Drahl, Organizers,
Presiding
Section B
Boston Convention & Exhibition Center
Room 253A/B
An Update on the War on Obesity
J. Macor, W. Ewing, Organizers, Presiding
The official technical program
for the 240th National Meeting
is available at:
www.acs.org/boston2010
MEDI
TECH–77